Sponsored Content
Evaluating Empagliflozin’s Impact on Cardiovascular Outcomes in Patients with T2D | AHA 2024
Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.
Episode 6: High Risk: Diabetes and COVID-19
In this episode of Over the Counter, 2 experts on diabetes management and care discuss the effect COVID-19 is having on individuals with diabetes and the ways that the health care system is responding.
Pharmacist-Led CGM Workflow Could Help Improve Diabetes Outcomes
A study found that a continuous glucose monitor workflow led by a pharmacist led to reduced HbA1c levels.
Greater Depression Severity Linked with Increased Diabetes Risk
A recent study found that with greater depression severity, metabolic and clinical characteristics such as HbA1c, fasting blood glucose, and triglyceride levels increased.
Q&A: Key Things Pharmacists Need to Know About Insulin Icodec
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses a recent meta-analysis that evaluated the efficacy, safety, and clinical implications of insulin icodec.
GLP-1, SGLT2 Prescriptions for Patients With T1D Increased Over Past Decade
A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.
